Who is sponsoring NCT01673282?

NCT01673282 is sponsored by UCB Pharma GmbH.

What drugs are being tested in NCT01673282?

Interventions in NCT01673282: Lacosamide.

What condition does NCT01673282 study?

NCT01673282 studies Focal Epilepsy With and Without Secondary Generalization.

Is NCT01673282 still recruiting?

NCT01673282 is currently completed. Last updated 26 September 2016.

Are results published for NCT01673282?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2016-09-26 · How we verify

NCT01673282: VICTOS

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Non-interventional, Observational Study Evaluating Changes in Drug Load and Seizure Frequency Using Vimpat (Lacosamide) in Daily Clinical Practice in Combination Therapy With Sodium Channel Blocking Anti-epileptic Drugs (AEDs) or Non Sodium Channel Blocking AEDs

Completed Results posted Last updated 26 September 2016

What this trial tests

trial testing Lacosamide in Focal Epilepsy With and Without Secondary Generalization in 315 participants. Completed in 1 July 2015.

Timeline

1 July 2012

Primary endpoint
1 July 2015

1 July 2015

Quick facts

Lead sponsor	UCB Pharma GmbH
Status	Completed
Study type	OBSERVATIONAL
Enrollment	315
Start date	1 July 2012
Primary completion	1 July 2015
Estimated completion	1 July 2015
Sites	42 locations across Austria, Germany

Drugs / interventions tested

Lacosamide (lacosamide) — full drug profile →

Conditions studied

Focal Epilepsy With and Without Secondary Generalization — all drugs for Focal Epilepsy With and Without Secondary Generalization →

Sponsor

UCB Pharma GmbH

Who can join

18 and older, any sex, with Focal Epilepsy With and Without Secondary Generalization. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

The Percent Change in Ratio of Dose and Defined Daily Dose (DDD) for the Drug Load of Concomitant Anti-Epileptic Drugs (AEDs) From Baseline to the End of Observation Period (Day 0 to 6 Months)
Time frame: From Baseline (Day 0) to 6 months
Drug load is defined as the sum of the ratios of the actual doses divided by the defined daily dose for all concomitant AEDs.

Sponsor's own description

This observational study aims to investigate how VIMPAT® is used as adjunctive therapy in clinical practice and will also evaluate the subsequent change in the drug load of patients after addition of VIMPAT® to their treatment regimen.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Changes in drug load during lacosamide combination therapy: A noninterventional, observational study in German and Austrian clinical practice.
Reinhardt F, Weber YG, Mayer T, Luef G, et al · · 2019 · cited 5× · PMID 31440722 · DOI 10.1002/epi4.12346

Verify or expand the search:

Other trials of Lacosamide

Trials testing the same drug.

NCT06969417 — Comparative Efficacy of Pregabalin and Lacosamide in Patients With Herpes Zoster and Post Herpetic Neuralgia · NA · recruiting
NCT05603702 — STTEPP: Safety, Tolerability and Dose Limiting Toxicity of Lacosamide in Patients With Painful Chronic Pancreatitis · Phase 1 · recruiting
NCT05510856 — Comparative Clinical Study Evaluating the Possible Efficacy of Duloxetine, Gabapentin and Lacosamide on Oxaliplatin-Indu · Phase 4 · completed
NCT05291455 — Lacosamide in Neonatal Status Epilepticus · Phase 3 · unknown
NCT04627285 — A Study to Test the Long-term Use of Oral Lacosamide in Pediatric Study Participants Who Completed NCT01964560 (EP0034) · Phase 3 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01673282 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by UCB Pharma GmbH
Last refreshed: 26 September 2016

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01673282.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing